Dosing & Administration

Spray the way to relief with a single-unit device1

ZOMIG® (zolmitriptan) Nasal Spray recommended dosing

  • ZOMIG Nasal Spray is not recommended in patients with moderate to severe hepatic impairment
  • If ZOMIG is co-administered with cimetidine, limit the maximum single dose of ZOMIG to
    2.5 mg, not to exceed 5 mg in any 24-hour period
  • Each ZOMIG Nasal Spray single-unit device delivers either a 2.5-mg or 5-mg dose of zolmitriptan
  • The safety of treating an average of more than 4 headaches with ZOMIG Nasal Spray in a 30-day period has not been established

Follow the 3 Steps Below

Encourage your patients to read all the instructions before using the ZOMIG Nasal Spray device for the first time.*



  • Remove the ZOMIG Nasal Spray unit from the single-use package it comes in. Do not remove the unit until you are ready to use it. The unit contains only 1 spray
  • Blow your nose gently before use
  • Remove the protective cap

2. SET

  • Hold the nasal sprayer device gently with your fingers and thumb as shown
    • NOTE: There is only one dose in the nasal sprayer. Do not try to prime the nasal sprayer or you will lose the dose. Do not press the plunger until you have put the tip into your nostril or you will lose the dose
  • Block one nostril by pressing firmly on the side of your nose. Either nostril can be used


  • Put the tip of the sprayer device into the other nostril as far as feels comfortable and tilt your head back slightly
    • NOTE: Do not press the plunger yet. Do not spray the contents of the device in your eyes
  • Breathe in slowly and gently through your nose, and at the same time press the plunger firmly with your thumb
    • NOTE: The plunger may feel stiff and you may hear a click
  • Keep your head slightly tilted back and remove the tip from your nose
  • Breathe gently through your mouth for 5 to 10 seconds
    • NOTE: You may feel liquid in your nose or the back of your throat. This is normal

*Dispose of the ZOMIG Nasal Spray device after completing the full dose or as soon as it becomes outdated or no longer needed. Dispose of properly. Keep out of reach of children. Do not reuse.

Nasal Spray Deposition5

ZOMIG® (zolmitriptan) Nasal Spray Deposition

Adapted with permission from SAGE.5

A cause-and-effect relationship between these data and clinical effect has not been established.

From an open, single-center, 2-phase trial designed to assess the distribution of zolmitriptan in the nasopharynx, lungs, and abdomen using positron emission tomography (PET) methodology after intranasal administration of zolmitriptan to
9 healthy volunteers.5

1ZOMIG® (zolmitriptan) Nasal Spray



  • ZOMIG is contraindicated in patients with
  • History of coronary artery disease (CAD) or coronary artery vasospasm
  • Symptomatic Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
  • History of stroke, transient ischemic attack, or hemiplegic or basilar migraine
  • Peripheral vascular disease
  • Ischemic bowel disease
  • Uncontrolled hypertension
  • Recent (within 24 hours) use of another 5-HT1 agonist (eg, another triptan), or an ergotamine-containing medication
  • Monoamine oxidase (MAO)-A inhibitor used in past 2 weeks
  • Known hypersensitivity to ZOMIG, ZOMIG-ZMT, or ZOMIG Nasal Spray. Anaphylaxis, anaphylactoid, and hypersensitivity reactions including angioedema have occurred in patients receiving zolmitriptan
  • Myocardial ischemia, myocardial infarction and Prinzmetal’s Angina: Perform cardiac evaluation in patients with multiple risk factors and, if satisfactory, administer first dose of ZOMIG in a medically supervised setting
  • Arrhythmias: Discontinue ZOMIG if these occur
  • Sensations of tightness, pain and pressure in the chest, throat, neck, and jaw commonly occur after treatment with 5-HT1 agonists like ZOMIG and are usually non-cardiac in origin: Perform a cardiac evaluation if these patients are at cardiac risk
  • Cerebrovascular events, some fatal; non-coronary Gastrointestinal Ischemic Reactions and Peripheral Vasospastic Reactions; and increases in blood pressure (which have been very rarely associated with serious clinical events) have been reported with ZOMIG. Discontinue use of ZOMIG if any of these events occur
  • Overuse of acute migraine drugs may lead to exacerbation headache (medication overuse headache). Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms may be necessary
  • Serotonin syndrome may occur with triptans, including ZOMIG, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors. Discontinue ZOMIG if serotonin syndrome is suspected
  • The most common adverse reactions in adults (≥5% and > placebo; in any dosage strength) in clinical trials for ZOMIG Nasal Spray were: unusual taste, paresthesia, hyperesthesia, and dizziness
  • The most common adverse reaction in pediatrics (age 12 to 17 years; ≥5% and > placebo; in either the 2.5 or 5 mg ZOMIG dose groups) in clinical trials for ZOMIG Nasal Spray was unusual taste


ZOMIG Nasal Spray is a serotonin (5-HT)1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years and older.

Limitations of Use:

Use ZOMIG only after a clear diagnosis of migraine has been established. If a patient has no response to ZOMIG treatment for the first migraine attack, reconsider the diagnosis of migraine before ZOMIG is administered to treat any subsequent attacks. ZOMIG is not indicated for the prevention of migraine attacks. Safety and effectiveness of ZOMIG have not been established for cluster headache. ZOMIG Nasal Spray is not recommended in patients with moderate to severe hepatic impairment.

Click here to see the full Prescribing Information for ZOMIG Nasal Spray  

Click here to see the full Prescribing Information for ZOMIG Tablets and ZOMIG-ZMT Orally Disintegrating Tablets  

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. To report SUSPECTED ADVERSE REACTIONS contact Impax Laboratories, Inc. at 1-877-994-6729.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.

This Web site contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other healthcare professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent healthcare decisions, you should always consult with a physician or other healthcare provider for your, or your loved one’s, personal medical needs. All quotes included in this Web site represent the individual experience of some doctors, some patients, and their caregivers. Individual responses to treatment may vary.

This site is intended for residents of the United States only. Any products discussed herein may have different product labeling in different countries.

US Flag This product information is intended for US healthcare professionals only.

ZOMIG and ZOMIG-ZMT are registered trademarks of the AstraZeneca group of companies.

© 2016 Impax Laboratories, Inc. All rights reserved. PP-ZNS-US-0028 3274901 09/2016